Efgartigimod developed by Argenx is a strong competitor to Soliris.
AstraZeneca
Posted inCOVID-19, Infections, Research
Omicron Variant: Latest Scientific News, Findings, Evidence, and Developments
Up-to-date scientific information about the new Omicron variant of SARS-CoV-2/COVID-19.
Posted inAutoimmune Diseases, Rare/Orphan Diseases, Regulatory
Ultomiris: First Drug for Paroxysmal Nocturnal Hemoglobinuria in Children and Adolescents
Alexion Pharmaceuticals’ ravulizumab has expanded the range of indications for treating a rare complement-mediated disease.
Posted inAutoimmune Diseases, New Drugs, Rare/Orphan Diseases, Regulatory
Empaveli: Powerful New Drug for Paroxysmal Nocturnal Hemoglobinuria
Pegcetacoplan is more effective in treating paroxysmal nocturnal hemoglobinuria compared to Soliris.
Posted inAutoimmune Diseases, Mergers & Acquisitions, Rare/Orphan Diseases
AstraZeneca + Alexion = Rescue of Both Companies
Alexion Pharmaceuticals, which owns Soliris, one of the most expensive drugs on Earth, has agreed to sell AstraZeneca for $39 billion.
Posted inNew Drugs, Rare/Orphan Diseases, Regulatory
Koselugo: First Drug to Treat Neurofibromatosis
Selumetinib by AstraZeneca powerfully suppresses tumor growth in neurofibromatosis type 1.
Posted inClinical Trials, In the Pipeline, Oncology, Regulatory
Small Cell Lung Cancer: Let Immunotherapy Help!
A deadly disease and modern pharmacological attempts to treat it.